Total submissions: 7
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic Laboratories, |
RCV000591895 | SCV007317844 | benign | not specified | 2024-06-14 | criteria provided, single submitter | clinical testing | BS1, BS2 |
| Ce |
RCV004715308 | SCV007115562 | benign | not provided | 2025-10-01 | criteria provided, single submitter | clinical testing | INF2: BS1, BS2 |
| Breakthrough Genomics, |
RCV004715308 | SCV005294720 | benign | not provided | criteria provided, single submitter | not provided | ||
| Labcorp Genetics |
RCV000861111 | SCV001001334 | benign | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2026-01-28 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV000591895 | SCV000714022 | benign | not specified | 2017-04-04 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
| Eurofins Ntd Llc |
RCV000591895 | SCV000707659 | benign | not specified | 2017-04-07 | criteria provided, single submitter | clinical testing | |
| Prevention |
RCV003915734 | SCV004731502 | benign | INF2-related disorder | 2019-03-18 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |